Crucell cuts 4th-qtr and full year 2007 losses

Dutch biotechnology firm Crucell NV says that its losses for the fourth quarter and full-year 2007 were 4.8 million euros ($7.0 million) and 45.9 million euros, respective improvements of 81% and 48% on the shortfalls recorded in final three months and full-year 2006.

4th-qtr sales stable

Revenue for the final three months of the year was 75.9 million euros, up just 100,000 on that recorded in the comparable period in 2006. Crucell said that this was because the contribution from influenza vaccine sales had, in 2006, been concentrated in the fourth quarter, whereas this year it was more evenly spread over the final six months of 2007.